5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 9.32▼ | 9.33▼ | 9.36▼ | 9.91▼ | 9.56▼ |
MA10 | 9.39▼ | 9.46▼ | 9.56▼ | 9.77▼ | 9.58▼ |
MA20 | 9.53▼ | 9.66▼ | 9.81▼ | 9.80▼ | 9.21▲ |
MA50 | 9.78▼ | 9.80▼ | 9.75▼ | 9.60▼ | N/A |
MA100 | 9.77▼ | 9.71▼ | 9.73▼ | 8.88▲ | N/A |
MA200 | 9.70▼ | 9.61▼ | 9.64▼ | N/A | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.011▼ | -0.049▼ | -0.082▼ | -0.015▼ | -0.471▼ |
RSI | 39.940▼ | 38.804▼ | 37.262▼ | 44.253▼ | 62.484▲ |
STOCH | 8.407▼ | 5.250▼ | 4.760▼ | 56.925 | 63.018 |
WILL %R | -100.000▼ | -100.000▼ | -100.000▼ | -95.098▼ | -52.709 |
CCI | -79.699 | -85.259 | -100.337▼ | -125.357▼ | 42.151 |
Wednesday, April 24, 2024 12:10 AM
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
26/04/24 | 9.75 | 9.818 | 9.30 | 9.35 | 205,822 |
25/04/24 | 9.93 | 10.2199 | 9.38 | 9.93 | 345,524 |
24/04/24 | 10.2399 | 10.24 | 9.69 | 10.24 | 15,607 |
23/04/24 | 10.00 | 10.20 | 9.8201 | 10.20 | 47,472 |
22/04/24 | 10.05 | 10.19 | 9.80 | 9.84 | 10,585 |
19/04/24 | 9.49 | 9.95 | 9.46 | 9.49 | 8,546 |
18/04/24 | 9.635 | 9.99 | 9.42 | 9.83 | 12,789 |
17/04/24 | 9.65 | 9.90 | 9.46 | 9.72 | 9,301 |
16/04/24 | 9.41 | 9.83 | 9.39 | 9.62 | 20,339 |
15/04/24 | 9.7175 | 9.88 | 9.33 | 9.50 | 13,342 |
|
|
||||
|
|
||||
|
|